- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Spinal muscular atrophy (SMA)
- Meeting Date: July 2024
- Public Summary Document (PSD) July 2024 PBAC Meeting - (PDF 832KB)
- Public Summary Document (PSD) July 2024 PBAC Meeting - (Word 143KB)
Risdiplam – July 2024
Risdiplam; Powder for oral solution 750 micrograms per mL, 80 mL; Evrysdi®
Last updated
30 May 2025